免疫治疗在胰腺导管腺癌中的研究现状  

Research Status of Immunotherapy in Pancreatic Ductal Adenocarcinoma

作　　者：赵杰 万金良[1] 王山 郝建斌 郝延璋[1] ZHAO Jie;WAN Jinliang;WANG Shan;HAO Jianbin;HAO Yanzhang

机构地区：[1]滨州医学院附属医院肿瘤科,山东滨州256603

出　　处：《中国医学创新》2024年第35期169-174,共6页Medical Innovation of China

摘　　要：胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDA)预后极差,是一种高致命性恶性肿瘤。目前临床治疗PDA的主要方法是手术切除,其他治疗方式以化疗为主,或者化疗联合放疗等。许多临床试验试图使用免疫方法治疗PDA,包括使用免疫检查点抑制剂、PDA疫苗、过继性T细胞疗法等,并尝试在免疫治疗基础上联合用药,当免疫治疗与其他方式相结合时,可以存在协同效应,使药物作用效果增强。在此篇综述中,我们阐述了免疫治疗在PDA中的现状、耐药机制及取得的成就、发展方向。Pancreatic ductal adenocarcinoma(PDA)has a very poor prognosis and is a highly lethal malignancy.At present,the main method of clinical treatment of PDA is surgical resection,other treatment methods are mainly chemotherapy,or chemotherapy combined with radiotherapy.Many clinical trials try to use immune methods to treat PDA,including the use of immune checkpoint inhibitors,PDA vaccine,adoptive T cell therapy,etc.,and try to combine drugs on the basis of immunotherapy,when immunotherapy is combined with other ways,there can be a synergistic effect to enhance the effect of drug action.In this review,we discuss the status,resistance mechanism,achievements and development direction of immunotherapy in PDA.

关 键 词：胰腺导管腺癌 免疫治疗 胰腺导管腺癌疫苗 CD40激动剂 过继性T细胞疗法 髓系细胞 

分 类 号：R735.9[医药卫生—肿瘤] R730.51[医药卫生—临床医学]